Drug intelligence / Profile preview

BG-2203

Development stage: Preclinical
Lead developer: Guangzhou Bio-gene Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BG-2203 is a CAR-T cell therapy currently in preclinical development for the treatment of solid tumors. It is being developed by Guangzhou Bio-gene Technology Co., Ltd. As a CAR-T therapy, it likely involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs) that can recognize and target specific antigens on cancer cells, particularly in solid tumors. The therapy is still in early stages of development, with its highest R&D status being preclinical as of March 2025.

Targets

BCMA (B-cell maturation antigen)GPRC5D

Beyond the preview

Go deeper on BG-2203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-2203.

Explore the full profile